Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Avanza; Azamianserin; ME-2040; Mepirzapin; Norset; ORG-3770; Promyrtil; Reflex; REFLEX Org3770; Remergil; Remergon; Remeron; RemeronSolTab; Rexer; Zispin

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Meiji Seika Pharma; Merck & Co
  • Class Dibenzazepines; Tetracyclic antidepressants
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists; Serotonin 2 receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Fibromyalgia

Most Recent Events

  • 12 Nov 2018 Mirtazapine is still in phase II trials for Fibromyalgia in Japan (Meiji Seika Pharma pipeline, November 2018)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2015 Phase-II development is ongoing for Fibromyalgia in Japan (PO) (Meiji Seika Pharma pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top